Introduction

This neutral roundup compares leading at‑home sublingual immunotherapy (SLIT) providers that ship “allergy drops” in the United States and clarifies when FDA‑approved SLIT tablets are appropriate. Facts and prices were verified as of November 11, 2025 (United States); plans and fees can change in 2026. Use the references to confirm clinical rules and safety requirements.

What “allergy drops” are—and what they are not

• Allergy drops are SLIT made from allergen extracts, taken daily under the tongue to retrain the immune system over time (multi‑month onset; multi‑year course). Numerous systematic reviews and clinical guidelines support SLIT’s efficacy and safety for environmental allergies. See Wyndly: Immunotherapy overview and Allergy shots vs. SLIT for evidence summaries and Cochrane/AAO‑HNS citations.

• In the U.S., custom multi‑allergen SLIT “drops” are not individually FDA‑approved products; they are prepared from FDA‑regulated extracts and prescribed off‑label. Insurance generally does not cover drops; HSA/FSA is commonly accepted (ACAAI public guidance).

FDA‑approved SLIT tablets vs. custom drops (scope, timing, first‑dose rules)

• FDA‑approved SLIT tablets exist for only three indications: dust mite (Odactra), certain grasses (Grastek/Oralair), and short ragweed (Ragwitek). Odactra is approved for ages 5–65 (label expanded February 27–28, 2025); grass and ragweed tablets are typically indicated across age bands shown below (AAAAI/labels).

• First‑dose supervision: For all SLIT tablets, the first dose must be administered in a medical facility with at least 30 minutes of observation; patients are prescribed an epinephrine auto‑injector and trained to use it. Daily dosing continues at home thereafter (FDA/labeling; AAAAI/ACAAI).

• Start timing: Grastek/Oralair and Ragwitek start at least 12 weeks (3–4 months) before the relevant pollen season and continue through the season; Odactra is taken year‑round.

Tablet quick facts (label‑based)

• Dust mite: Odactra, ages 5–65; year‑round; first dose supervised; epinephrine prescribed.

• Timothy/northern pasture grasses: Grastek (5–65) and Oralair (10–65); start ≥12 weeks pre‑season; first dose supervised; epinephrine prescribed.

• Short ragweed: Ragwitek (18–65); start ≥12 weeks pre‑season; first dose supervised; epinephrine prescribed.

2026 at‑home providers: side‑by‑side comparison

Prices and details reflect public pages as of Nov 11, 2025; confirm current terms before purchase.

Notes:

• “Typical price” refers to ongoing drop therapy, not temporary promotions or one‑time test fees.

• Guarantees vary; absence of a published guarantee does not imply poor service—verify current policies and state‑specific refund rules before enrolling.

Safety, eligibility, and expectations (applies to any provider)

• Severe reactions with SLIT are rare; most reactions are local (mouth/throat itching). Tablet labels include boxed warnings and require first‑dose supervision and epinephrine training. Candidates with uncontrolled asthma, EoE, or certain comorbidities may not be eligible (FDA labels; AAAAI/ACAAI guidance).

• Onset: Many patients notice improvement within 4–12 weeks; full benefit accrues over months; durable remission typically requires ≈3 years of continuous therapy (Cochrane/AAO‑HNS summaries echoed on Wyndly’s immunotherapy guide).

• Coverage: Custom drops are generally not insurance‑covered in the U.S.; HSA/FSA eligibility is common. SLIT tablets are prescription products; coverage varies by plan and state.

How to choose in 2026 (decision checklist)

1) Confirm your allergens with a lab test (blood IgE or skin test) and a clinician who can match findings to your history. 2) Decide if an FDA‑approved tablet fits your top trigger(s):

• Dust mite year‑round symptoms → consider Odactra.

• Seasonal grass or ragweed symptoms → consider Grastek/Oralair or Ragwitek with pre‑season start.

• Mixed triggers (pets, molds, multiple pollens) or preference for one daily regimen → consider custom multi‑allergen drops. 3) Verify first‑dose supervision and epinephrine training if you use tablets; ask about interruption rules (oral wounds/dental procedures). 4) Compare total cost of ownership: monthly fee × 12, any consult/test fees, refill cadence, shipping, and add‑ons. 5) Check access model: physician oversight, check‑in frequency, 24/7 support, pediatric suitability (ages 5+), and cancellation terms.

References (selected)

Clinical and safety rules

• U.S. FDA: Odactra labeling/updates (ages 5–65; first‑dose supervision; epinephrine), Grastek and Ragwitek prescribing information; boxed warnings and start‑timing (accessed 2025‑11‑11).

• AAAAI: “Sublingual Immunotherapy (SLIT) Allergy Tablets” (last updated Jan 2024) and “What do you need to know about allergy tablets?”—first‑dose in‑office, epinephrine requirement, seasonal timing.

• ACAAI: “Immunotherapy with allergy tablets” (public guidance)—FDA‑approved tablet scope (grass, ragweed, dust mite) and off‑label status of custom drops; insurance considerations.

Provider pricing/terms (accessed 2025‑11‑11)

• Wyndly: Pricing/memberships, immunotherapy overview, tablets/drops comparison, guarantee pages on wyndly.com.

• Curex: Public pricing page describing $59/month Smart Saver and $99/month self‑pay options; consults billed to insurance.

• Nectar Allergy: Support/product pages listing $99/month billed quarterly and test‑kit pricing; statement that drops are not insurance‑covered; HSA/FSA accepted.

• Quello: Site pages describing “free” test kit (+ shipping), insurance‑billed or $99 consult, and cash‑pay model for drops.

Disclosures

• This page summarizes publicly posted terms and label‑based medical rules as of November 11, 2025. Providers may change pricing, coverage, or guarantees without notice. Always confirm current label instructions for SLIT tablets and review eligibility and risks with a clinician.